预约演示
更新于：2025-04-21
Mosapride Citrate Hydrate
枸橼酸莫沙必利
更新于：2025-04-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1998-06-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H37ClFN3O12 |
InChIKeyKVKIQHMTGSGTFO-UHFFFAOYSA-N |
CAS号636582-62-2 |
关联
69
项与 枸橼酸莫沙必利 相关的临床试验NCT06826443
A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
NCT06782594
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction
CTR20242912
一项评价枸橼酸莫沙必利注射液治疗术后胃肠功能障碍的多中心、随机、双盲、平行、安慰剂对照的II期临床研究
100 项与 枸橼酸莫沙必利 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸莫沙必利 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸莫沙必利 相关的专利（医药）
登录后查看更多信息
422
项与 枸橼酸莫沙必利 相关的文献（医药）2025-12-31PHARMACEUTICAL BIOLOGY
Article
作者: Choi, Yu-Jin ; Wang, Jing-Hua ; Hwang, Seung-Ju ; Lee, Jin-Seok ; Woo, Tae-Wook ; Kim, Dong-Seon ; Son, Chang-Gue ; Seo, Chang-Seob ; Baek, Dong-Cheol ; Gu, Ji-Yeon
CONTEXT:
WDJ-S4, a standardized herbal formula, has been prescribed for refractory functional dyspepsia (FD) in Korea, but the detailed mechanisms are lacking.
OBJECTIVE:
The present study investigates the acceleration of gastrointestinal (GI) motility by WDJ-S4 and its potential mechanisms.
MATERIALS AND METHODS:
For five days, WDJ-S4 (50, 100 and 200 mg/kg) or mosapride (3 mg/kg) was orally given to BALB/c mice. After 20 h of fasting, loperamide (10 mg/kg, i.p.) was given to the mice except for normal group. To assess gastric emptying or intestinal propulsion, 500 μL of 0.05% phenol red or 200 μL of 5% charcoal diet was given once orally.
RESULTS:
Loperamide delayed gastric emptying and intestinal propulsion, while WDJ-S4 ameliorated peristaltic dysfunction, evidenced by reductions of remaining phenol red in the stomach and a marked increase of charcoal propulsion in the intestine. WDJ-S4 also normalized levels of acetylcholine and acetylcholine-related enzymes, including choline acetyltransferase (ChAT) and acetylcholinesterase (AChE), in the gastric antrum and jejunum. C-kit level and smooth muscle contraction-related genes were elevated by WDJ-S4 in both the gastric antrum and jejunum.
CONCLUSION:
Overall, WDJ-S4 can effectively promote GI motility. The efficacy is associated with modulation of acetylcholine pathway and the interstitial cells of Cajal (ICCs) activation. All the results provide scientific evidence supporting the clinical usage of WDJ-S4 for FD.
2025-02-01FOOD CHEMISTRY
Theaflavin-3,3′-digallate (TF3) attenuated constipation by promoting gastrointestinal motility and modulating the gut microbiota: A comparative study of TF3 and the anti-constipation drug mosapride in mice
Article
作者: Huang, Haitao ; Wan, Xiaochun ; Liu, Junsheng ; Wu, Yuanyuan ; Li, Bo ; Wu, Tingbo ; Yang, Mingxue ; Yu, Haonan ; Tu, Youying ; Jin, Leyi
TF3 is a functional pigment formed during the process of black tea. This study aims to explore the anti-constipation effects of TF3 and compare its efficacy with the anti-constipation drug mosapride. Result showed that both TF3 and mosapride increased fecal water content and promoted gastrointestinal (GI) motility, but TF3 was more effective in restoring excitatory neurotransmitters like gastrin (Gas), motilin (MTL), and substance P (SP). TF3 uniquely altered the gut microbiota profile and restored the bacterial community at the phylum level. TF3 targeted specific bacteria such as Alloprevotella, Bacteroides, and Parabacteroides, while mosapride affected different bacterial groups. Significant changes in Bacteroides and Prevotellaceae UCG-001 were linked to constipation improvement. Importantly, TF3 did not synergize with mosapride in alleviating constipation. These findings highlight TF3's unique role in modulating gut microbiota to relieve constipation and suggest great potential to develop functional foods with anti-constipation properties using tea-derived polyphenols.
2024-09-01Respiratory Investigation
Gastroesophageal reflux disease in chronic obstructive pulmonary disease
Review
作者: Tanimura, Kazuya ; Muro, Shigeo
Gastroesophageal reflux disease (GERD) is one of the most common comorbidities of chronic obstructive pulmonary disease (COPD). Decreased lower and upper esophageal sphincter pressures, esophageal dysmotility, high transdiaphragmatic pressure, and decreased saliva secretion have been implicated as mechanisms leading to the development of GERD in COPD. Clinically, comorbid GERD in COPD is reportedly associated with worse symptoms, quality of life, and lung function, as well as a high risk of exacerbations. Aspiration of regurgitation and the cholinergic-mediated esophagobronchial reflex play a significant role in the pathophysiology. Abnormal swallowing reflexes and discoordination of swallowing can worsen aspiration. The diagnosis of GERD is not based on a single criterion; however, various approaches, including questionnaires and endoscopic evaluations, can be widely applied in clinical settings. Due to the increased risk of esophageal and gastric cancers in patients with COPD, the threshold for endoscopic examination should be low. Acid inhibitory agents, such as proton pump inhibitors and histamine H2 receptor antagonists, and prokinetic agents, including mosapride and itopride, are clinically used to treat GERD. Endoscopic fundoplication can be performed in patients with GERD refractory to medical treatment. There is still insufficient evidence, but an increasing number of studies have suggested the clinical efficacy of treatment in patients with COPD and GERD. As GERD is an evaluative and treatable common disease, and access to evaluation and treatment is relatively easy, clinicians should provide adequate care for GERD in the management of COPD.
100 项与 枸橼酸莫沙必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 中国 | 2005-08-31 | |
| 泌尿结石 | 中国 | 1999-01-01 | |
| 慢性胃炎 | 日本 | 1998-06-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化不良 | 临床3期 | 韩国 | 2016-12-12 | |
| 胃肠功能紊乱 | 临床2期 | 中国 | 2024-10-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鑰糧鏇餘窪願憲遞簾衊(網鹹艱窪壓鏇襯網鏇廠) = 膚觸觸蓋醖鑰遞鏇齋醖 齋網積糧網淵簾網顧積 (襯遞憲繭糧醖網鏇範鹽 ) 更多 | 积极 | 2023-10-15 | |||
Placebo | 鑰糧鏇餘窪願憲遞簾衊(網鹹艱窪壓鏇襯網鏇廠) = 餘觸餘範鏇淵願製壓願 齋網積糧網淵簾網顧積 (襯遞憲繭糧醖網鏇範鹽 ) 更多 | ||||||
N/A | 消化不良 hydrogen | methane | - | 餘艱廠願鑰鹽選簾選獵(夢網範醖選鏇憲壓選齋) = 鹹鬱齋淵餘簾願糧蓋顧 遞築蓋範繭遞觸膚築鏇 (壓鹽願製餘衊積選顧糧 ) | 不佳 | 2022-05-22 | ||
餘艱廠願鑰鹽選簾選獵(夢網範醖選鏇憲壓選齋) = 製鏇鑰網窪膚膚築範憲 遞築蓋範繭遞觸膚築鏇 (壓鹽願製餘衊積選顧糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用